Pharmaceutical compositions
AssigneeHoechst Aktiengesellschaft
InventorsHeinz-Joachim Hinze, Alfons Soder, Kurt Popendiker
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition containing as an essential ingredient a compound of the formula ##STR1## wherein one of the groups R.sub.1, R.sub.2 and R.sub.3 is an .omega.- or (.omega.-1)-hydroxyalkyl group having from 5 to 8 carbon atoms in which the hydroxy group is separated from the xanthine nucleus by at least 2 carbon atoms, radicals R.sub.1 and R.sub.3 which are no hydroxyalkyl group, are hydrogen or methyl and equal or different, and R.sub.2 is said hydroxyalkyl group or methyl, a compound of formula (I) and a pharmaceutical product for treatment of diseases involving insufficiency of cerebral blood flow.
Claims5
A cerebral-blood-flow increasing pharmaceutical composition containing, as one of plural components and as sole active ingredient, an effective amount of a compound of the formula ##STR3## wherein R.sub.1 is a member selected from the group consisting of .omega.-hydroxyalkyl having from 5 to 8 carbon atoms and in which the hydroxyl is separated from the xanthine nucleus by at least two carbon atoms, unbranched (.omega.-1)-hydroxyalkyl having 5 to 8 carbon atoms, branched (.omega.-1)-hydroxyalkyl having from 5 to 8 carbon atoms and in which the hydroxyl is separated from the xanthine nucleus by at least two carbon atoms, methyl and --H;
- R.sub.2 is a member selected from the group consisting of .omega.-hydroxyalkyl having from 5 to 8 carbon atoms and in which the hydroxyl is separated from the xanthine nucleus by at least two carbon atoms, unbranched (.omega.-1)-hydroxyalkyl having from 5 to 8 carbon atoms, branched (.omega.-1)-hydroxyalkyl having from 5 to 8 carbon atoms and in which the hydroxyl is separated from the xanthine nucleus by at least two carbon atoms, and methyl;
- and
- R.sub.3 is a member selected from the group consisting of .omega.-hydroxyhexyl, unbranched (.omega.-1)-hydroxyalkyl having from 5 to 8 carbon atoms, branched (.omega.-1)-hydroxyalkyl having from 5 to 8 carbon atoms and in which the hydroxyl is separated from the xanthine nucleus by at least two carbon atoms, methyl and --H;
- one and only one of R.sub.1, R.sub.2 and R.sub.3 being .omega.- or (.omega.-1)-hydroxyalkyl.
A method of improving cerebral blood circulation which comprises administering to a person afflicted with insufficiency of cerebral blood circulation a cerebral-blood-circulation-improving effective amount of a sterile aqueous or solid pharmaceutically-acceptable composition containing
- a. a pharmaceutically-acceptable diluent for active ingredient in the composition and
- b. a sufficient concentration of active ingredient to counteract insufficiency of cerebral blood circulation in a host to which the composition is administered;
- one of plural components and the sole essential active ingredient of the composition being a compound of the formula ##STR4## wherein one of R.sub.1 and R.sub.3 is unbranched (.omega.-1-monohydroxyalkyl) having from 5 to 8 carbon atoms and the other is methyl.
A method improving cerebral blood circulation which comprises administering to a person afflicted with insuffieciency of cerebral blood circulation from 0.2 to 20 milligrams per kilogram of body weight of a compound of the formula ##STR5## wherein either R.sub.1 is unbranched (.omega.-1) -monohydroxyalkyl having 5 to 8 carbon atoms and R.sub.3 is methyl or R.sub.1 is methyl and R.sub.3 is unbranched (.omega.-1)-monohydroxyalkyl having 5 to 8 carbon atoms.
A non-toxic pharmaceutical composition for increasing cerebral blood flow, comprising a sole active component in addition to carrier, diluent or excipient and characterized by the active component which is an effective amount of a compound of the formula ##STR6## wherein R.sub.1 is a member selected from the group consisting of .omega.-hydroxyalkyl having from 5 to 8 carbon atoms and in which the hydroxyl is separated from the xanthine nucleus by at least two carbon atoms, unbranched (.omega.-1)-hydroxyalkyl having 5, 7 or 8 carbon atoms, branched (.omega.-1)-hydroxyalkyl having from 5 to 8 carbon atoms and in which the hydroxyl is separated from the xanthine nucleus by at least two carbon atoms, methyl and --H;
- R.sub.2 is a member selected from the group consisting of .omega.-hydroxyalkyl having from 5 to 8 carbon atoms and in which the hydroxyl is separated from the xanthine nucleus by at least two carbon atoms, unbranched (.omega.-1)-hydroxyalkyl having from 5 to 8 carbon atoms, branched (.omega.-1)-hydroxyalkyl having from 5 to 8 carbon atoms and in which the hydroxyl is separated from the xanthine nucleus by at least two carbon atoms, and methyl;
- and
- R.sub.3 is a member selected from the group consisting of .omega.-hydroxyhexyl, unbranched (.omega.-1)-hydroxyalkyl having from 5 to 8 carbon atoms, branched (.omega.-1)-hydroxyalkyl having from 5 to 8 carbon atoms and in which the hydroxyl is separated from the xanthine nucleus by at least two carbon atoms, methyl and --H;
- one and only one of R.sub.1, R.sub.2 and R.sub.3 being .omega.- or (.omega.-1)-hydroxyalkyl.
Dependencies are inferred from the claim text.